Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.710
-0.890 (-34.23%)
At close: Sep 3, 2026, 4:00 PM EDT
1.680
-0.030 (-1.75%)
Pre-market: Sep 4, 2026, 6:37 AM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
3.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
| Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
| Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
| Dec 31, 2015 | 33.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Curis | 4.31M |
| 60 Degrees Pharmaceuticals | 1.21M |
| SciSparc | 856.00K |
| GeoVax Labs | 852.28K |
| Onconetix | 645.82K |
| BioRestorative Therapies | 357.87K |
APVO News
- 19 hours ago - Aptevo AML data ‘highly encouraging,’ says Roth Capital - TheFly
- 22 hours ago - Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia - TheFly
- 22 hours ago - Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - Accesswire
- 13 days ago - Aptevo Therapeutics files to sell 6.44M shares of common stock for holders - TheFly
- 18 days ago - Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds - TheFly
- 18 days ago - Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30 - TheFly
- 20 days ago - Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Accesswire
- 21 days ago - Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - Accesswire